Navigation Links
Gladstone scientists uncover potential mechanism of memory loss in Alzheimer's disease
Date:9/5/2007

SAN FRANCISCO, CA -- September 6, 2007 -- Researchers at the Gladstone Institute of Neurological Disease (GIND) and Baylor College of Medicine have discovered a mechanism by which the protein Amyloid-beta(AB) may impair neurological functions in Alzheimer's disease. AB, which is known to accumulate in the brains of Alzheimer patients, has long been a focus of research into the causes and treatment of the disease. In a study published in the journal Neuron, Gladstone scientists found that A-beta triggers abnormal overexcitation of the very brain networks that are responsible for learning and memory.

"Such abnormal network activity in Alzheimer's patients was thought to be a collateral or secondary event caused by the degeneration of nerve cells," said Jorge J Palop, PhD, Gladstone research scientist and lead author of the study. "But our study suggests that this activity may actually be a primary effect of A-beta and an early determinant of cognitive failure."

The Gladstone team used several genetically engineered mouse models of AD in which memory deficits are triggered by a human gene that causes high levels of A-beta. They discovered that high levels of A-beta induce an insidious type of seizure activity in learning and memory centers that is not accompanied by the usual twitching and jerking movements seen in many forms of epilepsy. In fact, it took sophisticated brain wave recordings in freely behaving mice by electroencephalography (EEG) and telemetry to detect the seizure activity.

"We were really surprised by these findings because A-beta had previously been suspected to primarily suppress neuronal activity," said Lennart Mucke, MD, GIND director and professor of neurology and neuroscience at the University of California, San Francisco (UCSF), and senior author of the study. "This abnormal brain activity could play an important role in the development of Alzheimer-related cognitive impairments."

Physicians have long recognized that Alzheimer patients have a higher incidence of convulsive seizures than reference populations. The new study indicates that A-beta is to blame for this problem and raises the disconcerting possibility that these patients may also have non-convulsive seizures that could easily escape detection by standard clinical exams. The investigators are eager to test this hypothesis in a planned follow-up study of human subjects.

"Our results have important therapeutic implications, because the prevention and reversal of non-convulsive seizure activity has not yet been a major focus of clinical trials in Alzheimer's disease. Our results suggest that the suppression of this activity might prevent and possibly even reverse cognitive impairments induced by high levels of A-beta," said Dr. Mucke.


'/>"/>

Contact: Valerie Tucker
vtucker@gladstone.ucsf.edu
415-734-2019
Gladstone Institutes
Source:Eurekalert

Related biology technology :

1. UW computer scientists fighting computer virus "Cold War"
2. Scientists find way to make human collagen in lab
3. Wisconsin scientists to be recognized for innovative biofuel technology
4. UW-Madison scientists to mimic nature for newest cancer drugs
5. UW scientists study strange material with communications potential
6. Scientists find nanotech method for examining cells
7. UW space scientists use Keck telescope to study wild weather of Uranus
8. UW computer scientists tout achievements and explain industry shortcomings
9. Facing shortage of U.S. scientists, UW wants to boost math enrollment
10. UW-Madison scientists find a key to cell division
11. TIP/UW Scientists Provide Mars Rover Commentary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)...  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company ... autoimmune diseases, asthma and allergic diseases and cancer, ... and full year ended December 31, 2016 and ... and clinical highlights. "During 2016, we ... by starting five clinical trials across our XmAb ...
(Date:2/28/2017)... ... February 28, 2017 , ... FireflySci is a small cuvette manufacturer ... late 2014, FFS had a mission to bring affordable and quality lab equipment to ... product that gives a lab everything needed to get started with using cuvettes. , ...
(Date:2/28/2017)... ... February 28, 2017 , ... ACEA Biosciences, a pioneer in cell analysis instrumentation ... Dr. Roger (Feng) Luo as the new Vice President of Global Clinical Development. ... drug companies, Dr. Luo will now team with Dr. Li Xu, Chief Medical Officer, ...
(Date:2/28/2017)... ... February 28, 2017 , ... GigaGen ... from millions-diverse immune repertoires, today announced a strategic partnership with Trianni, Inc. ... to express human antibodies. The partnership will use GigaGen technology to discover immuno-oncology ...
Breaking Biology Technology:
(Date:2/3/2017)... 2017 A new independent identity strategy consultancy ... (IdSP) . Designed to fill a critical niche in ... founding partners Mark Crego and Janice ... in identity expertise that span federal governments, the 9/11 ... Crego-Kephart combined expertise has a common theme born from ...
(Date:1/31/2017)... Mass. , Jan. 31, 2017  Spero ... novel therapies for the treatment of bacterial infections, ... set of antibacterial candidates from Pro Bono Bio ... increased prevalence of multi-drug resistant forms of Gram-negative ... Cantab Anti Infectives Ltd, a PBB group company. ...
(Date:1/24/2017)... YORK , Jan. 24, 2017 ... study of the laboratory use of nuclear magnetic ... 363 experienced end-users and profiled current practices, developments, ... years, as well as growth and opportunities. These ... Instrument suppliers, NMR instruments, needs and innovation requirements, ...
Breaking Biology News(10 mins):